1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
644B1CD6F21CC3E72002586B800665709
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/44B1CD6F21CC3E72002586B800665709?OpenDocument
18
19OpenDocument
2035.170.64.36
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Product Launch » Product Launch Excellence

Document Excerpt: Pharmaceutical Product Launch Evaluation Excellence: Key Performance Measures

DB Image

ID: MD-777


Features:

7 Info Graphics

19 Data Graphics

180+ Metrics

8 Narratives


Pages/Slides: 4


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "add to cart" on the right.

To return to the study abstract to purchase the full study - click here

This excerpt includes research findings and metrics from document #5677 "Pharmaceutical Product Launch Evaluation Excellence: Key Performance Measures."

Industries Profiled:
Biotech; Pharmaceutical; Health Care; Biopharmaceutical; Clinical Research; Laboratories; Consumer Products; Chemical; Medical Device; Communications; Consulting


Companies Profiled:
Amgen; Sanofi; Merck; Novartis; Eisai; Genentech; Sunovion; Grünenthal; GlaxoSmithKline ; Novo Nordisk; UCB Pharma; BIOCAD; Sanofi Genzyme; ASC Therapeutics; APR Applied Pharma Research; Prothena; Karyopharm Therapeutics; Alcon; Arvelle Therapeutics; BeiGene; Dendreon; NexGen Healthcare Communications; MEDiSTRAVA; Klosterfrau Healthcare Group; Kala Pharmaceuticals; Inc.; Bioviiix; Nutricia; Scilex Pharmaceuticals; NeuroTau; Medexus Pharmaceuticals; Theravance; Supernus; Viatris

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.